2021
DOI: 10.3389/fonc.2021.762528
|View full text |Cite
|
Sign up to set email alerts
|

FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

Abstract: The fibroblast growth factor-4 receptor (FGFR4) is a member of receptor tyrosine kinase. The FGFR4 Gly388Arg polymorphism in the transmembrane domain of the receptor has been shown to increase genetic susceptibility to cancers. However, its prognostic impact in cancer patients still remains controversial. Herein, we performed this meta-analysis to evaluate the clinicopathological and prognostic impacts of the FGFR4 Gly388Arg polymorphism in patients with cancer. We carried out a computerized extensive search u… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 72 publications
0
2
0
Order By: Relevance
“…In our case, the molecular-genetic analysis of the tumor showed controversial data: stable MSS status and low tumor mutation burden, but positive PD-L1 IHC and qPCR, overexpression of PD-1, TIGIT, CTLA4, IDO1, and LAG3 were identified. Using next-generation sequencing, FGFR p.G388R was found, and this variant was earlier identified in cancer patients with a high risk of recurrence and poor outcome [ 33 , 34 ]. In addition, expression analysis showed the progression phenotype of this tumor: adenosine A2b receptor was found to be a driver of progression in oral SCC cancer, and TGF-beta can undergo a conversion from tumor suppressor to tumor promoter in squamous cell cancer [ 35 , 36 ].…”
Section: Discussionmentioning
confidence: 99%
“…In our case, the molecular-genetic analysis of the tumor showed controversial data: stable MSS status and low tumor mutation burden, but positive PD-L1 IHC and qPCR, overexpression of PD-1, TIGIT, CTLA4, IDO1, and LAG3 were identified. Using next-generation sequencing, FGFR p.G388R was found, and this variant was earlier identified in cancer patients with a high risk of recurrence and poor outcome [ 33 , 34 ]. In addition, expression analysis showed the progression phenotype of this tumor: adenosine A2b receptor was found to be a driver of progression in oral SCC cancer, and TGF-beta can undergo a conversion from tumor suppressor to tumor promoter in squamous cell cancer [ 35 , 36 ].…”
Section: Discussionmentioning
confidence: 99%
“…Loss of FGFR protein activity regulation is reported to be oncogenic leading to the overexpression of FGFR protein [ 32 ]. Another study has shown that the G388R in the protein kinase domain on FGFR4 has been proven to increase the potential of promoting cancer cells [ 33 ].…”
Section: Discussionmentioning
confidence: 99%